Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma

BACKGROUND AND AIMS: In this pilot study, we assessed the safety and tolerability of combining sorafenib with (90)Y radioembolization for the treatment of unresectable hepatocellular carcinoma (hcc). METHODS: The study, conducted prospectively during 2009–2012, included eligible patients with unrese...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Curr Oncol
Päätekijät: Salman, A., Simoneau, E., Hassanain, M., Chaudhury, P., Boucher, L.M., Valenti, D., Cabrera, T., Nudo, C., Metrakos, P.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Multimed Inc. 2016
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5081020/
https://ncbi.nlm.nih.gov/pubmed/27803608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.23.2827
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia